Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349 | 0.85 | GLA (0.40) | PDPK1GDAALDH1A1HTTRECQL | |
| SCHEMBL13851103 | 0.81 | UMPS (0.40) | PDPK1CDK8CCNCCCNA2CDK2 | |
| SCHEMBL2588574 | 0.81 | HCAR2 (0.38) | PDPK1CDK8CCNCCCNA2CDK2 | |
| SCHEMBL13815833 | 0.77 | HCAR2 (0.32) | PDPK1CDK8CCNCHCAR2 | |
| SCHEMBL13211644 | 0.74 | PDPK1 (0.45) | PDPK1GDACCNA2CDK2CCNA1 | |
| SCHEMBL1527741 | 0.74 | SMN1; SMN2 (0.41) | CDK8CCNCKDM4EALDH1A1HPGD | |
| SCHEMBL6336859 | 0.74 | PDPK1 (0.41) | PDPK1CDK8CCNCGDACCNA2 | |
| SCHEMBL3804253 | 0.73 | GAA (0.40) | PDPK1CDK8CDK19GABRPGABRD | |
| SCHEMBL5054555 | 0.73 | PDPK1 (0.35) | PDPK1UMPS | |
| SCHEMBL16972561 | 0.72 | PDPK1 (0.33) | PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102267986-B | Pyrazole bisamide compounds as well as synthesis method and application thereof | UNIV CHINA AGRICULTURAL | 2014-04-16 | — | — | CN | disclosed |
| CN-102267986-A | Pyrazole bisamide compounds as well as synthesis method and application thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| CN-100383141-C | Pyrazolo [4,3-d] pyrimidine derivatives | PFIZER (US) | 2008-04-23 | — | — | CN | disclosed |
| CN-100378100-C | Pyrazolo(4,3-d)pyrimidine derivatives | PFIZER (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1149579-A2 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001051042-A2 | TREATMENT OF DIABETIC ULCERS | PFIZER LIMITED (GB) | 2001-07-19 | — | — | WO | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001027112-A1 | 5-(2-SUBSTITUTED-5-HETEROCYCLYLSULPHONYLPYRID-3-YL)-DIHYDROPYRAZOLO[4,3-D]PYRIMIDIN-7-ONES AS PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| CN-1253561-A | Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | PFIZER LTD (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0995750-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | PDPK1 1904/4885CDK8 751/4885CCNC 1189/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | PDPK1 1565/4885CDK8 2974/4885CCNC 3401/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDPK1 2359/4885CDK8 3404/4885CCNC 2568/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDPK1 2359/4885CDK8 3404/4885CCNC 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.